N N Zhang1, W Lu2, X J Cheng1, J Y Liu1, Y H Zhou1, F Li1. 1. Tianjin Second People's Hospital, 7 Sudi Road, Tianjin 300192, China; Tianjin Institute of Hepatology, 7 Sudi Road, Tianjin 300192, China. 2. Tianjin Second People's Hospital, 7 Sudi Road, Tianjin 300192, China; Tianjin Institute of Hepatology, 7 Sudi Road, Tianjin 300192, China. Electronic address: mail4luwei@163.com.
Abstract
AIM: To evaluate the safety and efficacy of high-powered (80-100 W) percutaneous microwave ablation (MWA) at a frequency of 2450±10 MHz for treating larger hepatocellular carcinoma (HCC) and to predict the risk factors of local recurrence after high-powered MWA. MATERIALS AND METHODS: The study was approved by the Institutional Review Board, and informed consent was waived because of the retrospective study design. Forty-five patients with a total of 60 lesions received high-power (80-100 W) MWA at a frequency of 2450±10 MHz through a percutaneous approach that was guided by ultrasound. Of the 60 lesions with a maximum tumour measuring 3-8 cm, 46 lesions were 3-5 cm and 14 were 5-8 cm. The complete ablation rates, local recurrence rates, complications, and short-term survival were analysed. Ten possible risk factors for local recurrence were analysed. RESULTS: The complete ablation rates were 82.61% for the first ablation and 100% for the second ablation for 3-5 cm lesions. The complete ablation rates were 64.29% (82.61% versus 64.29%, p=0.037) for the first ablation and 85.71% (100% versus 85.71%, p=0.055) for the second ablation for 5-8 cm lesions. Local recurrence was observed in 11 out of the 45 (24.44%) successfully treated patients. The 1-year and 2-year survival rates were 95.56% (43/45) and 86.67% (39/45), respectively. No procedure-related mortality was observed and no major bleeding, liver rupture, or liver abscesses occurred. Univariate analysis showed that a positive correlation existed between the number of lesions (p=0.022), proximity to the risk area (p=0.001), pre-ablation alpha-fetoprotein (AFP) levels (p=0.025), hepatitis B virus (HBV)-DNA replication (p=0.027) and local recurrence. Multivariate analysis identified HBV-DNA (p=0.031) and proximity to the risk area (p=0.039) as the independent prognosis factors causing postoperative HCC local recurrence. CONCLUSION: High-powered MWA of larger hepatocellular carcinomas appears to be a safe and effective treatment. HBV-DNA and proximity to the risk area appear to be independent predictors of local tumour recurrence.
AIM: To evaluate the safety and efficacy of high-powered (80-100 W) percutaneous microwave ablation (MWA) at a frequency of 2450±10 MHz for treating larger hepatocellular carcinoma (HCC) and to predict the risk factors of local recurrence after high-powered MWA. MATERIALS AND METHODS: The study was approved by the Institutional Review Board, and informed consent was waived because of the retrospective study design. Forty-five patients with a total of 60 lesions received high-power (80-100 W) MWA at a frequency of 2450±10 MHz through a percutaneous approach that was guided by ultrasound. Of the 60 lesions with a maximum tumour measuring 3-8 cm, 46 lesions were 3-5 cm and 14 were 5-8 cm. The complete ablation rates, local recurrence rates, complications, and short-term survival were analysed. Ten possible risk factors for local recurrence were analysed. RESULTS: The complete ablation rates were 82.61% for the first ablation and 100% for the second ablation for 3-5 cm lesions. The complete ablation rates were 64.29% (82.61% versus 64.29%, p=0.037) for the first ablation and 85.71% (100% versus 85.71%, p=0.055) for the second ablation for 5-8 cm lesions. Local recurrence was observed in 11 out of the 45 (24.44%) successfully treated patients. The 1-year and 2-year survival rates were 95.56% (43/45) and 86.67% (39/45), respectively. No procedure-related mortality was observed and no major bleeding, liver rupture, or liver abscesses occurred. Univariate analysis showed that a positive correlation existed between the number of lesions (p=0.022), proximity to the risk area (p=0.001), pre-ablation alpha-fetoprotein (AFP) levels (p=0.025), hepatitis B virus (HBV)-DNA replication (p=0.027) and local recurrence. Multivariate analysis identified HBV-DNA (p=0.031) and proximity to the risk area (p=0.039) as the independent prognosis factors causing postoperative HCC local recurrence. CONCLUSION: High-powered MWA of larger hepatocellular carcinomas appears to be a safe and effective treatment. HBV-DNA and proximity to the risk area appear to be independent predictors of local tumour recurrence.
Authors: Maria Franca Meloni; Jason Chiang; Paul F Laeseke; Christoph F Dietrich; Angela Sannino; Marco Solbiati; Elisabetta Nocerino; Christopher L Brace; Fred T Lee Journal: Int J Hyperthermia Date: 2016-08-02 Impact factor: 3.914
Authors: C Matthew Hawkins; Alexander J Towbin; Derek J Roebuck; Eric J Monroe; Anne E Gill; Avnesh S Thakor; Richard B Towbin; Anne Marie Cahill; Matthew P Lungren Journal: Pediatr Radiol Date: 2018-02-02
Authors: Neal Bhutiani; Prejesh Philips; Charles R Scoggins; Kelly M McMasters; Melissa H Potts; Robert C G Martin Journal: HPB (Oxford) Date: 2016-05-01 Impact factor: 3.647
Authors: Pierpaolo Biondetti; Enrico Maria Fumarola; Anna Maria Ierardi; Andrea Coppola; Giovanna Gorga; Luca Maggi; Elena Valconi; Salvatore Alessio Angileri; Gianpaolo Carrafiello Journal: Med Oncol Date: 2020-04-02 Impact factor: 3.064
Authors: Robert M Pohlman; James L Hinshaw; Timothy J Ziemlewicz; Meghan G Lubner; Shane A Wells; Fred T Lee; Marci L Alexander; Kelly L Wergin; Tomy Varghese Journal: Ultrasound Med Biol Date: 2021-05-16 Impact factor: 3.694
Authors: Anna Maria Ierardi; Pierpaolo Biondetti; Andrea Coppola; Enrico Maria Fumarola; Alberto Magenta Biasina; Salvatore Alessio Angileri; Gianpaolo Carrafiello Journal: Gland Surg Date: 2018-04